Yilin Meng
About Yilin Meng
Yilin Meng is a Principal Scientist at Bristol Myers Squibb in Cambridge, Massachusetts, specializing in computational techniques for drug discovery.
Company
Yilin Meng is currently employed at Bristol Myers Squibb, a prominent pharmaceutical company, in Cambridge, Massachusetts, United States. Bristol Myers Squibb is known for its innovative research and development in the healthcare sector, particularly focusing on serious diseases. Yilin has held multiple positions within the company, contributing significantly to their drug discovery initiatives.
Title
Yilin Meng holds the position of Principal Scientist at Bristol Myers Squibb. In this role, Yilin supports various drug discovery teams by leveraging advanced computational techniques. Previously, Yilin had also served as a Sr. Research Investigator II at the same company.
Education and Expertise
Yilin Meng has a Ph.D. in Computational Chemistry from the University of Florida, where extensive research was conducted from 2004 to 2010. Before that, Yilin completed a Bachelor of Engineering in Chemical Engineering from Dalian University of Technology. Yilin's expertise lies in computational chemistry, particularly in techniques such as molecular docking, QSAR, molecular dynamics simulations, free energy calculations, and quantum mechanical calculations.
Professional Background
Before the current tenure at Bristol Myers Squibb, Yilin Meng worked as a Senior Scientist at Pfizer from 2017 to 2020. At the University of Chicago, Yilin served as a Staff Scientist for a year and as a Postdoctoral Researcher for six years. These roles provided deep insights into drug discovery and applied computational methodologies for scientific research and development.
Research and Development Initiatives
Yilin Meng is actively involved in several drug discovery projects, including Rule-of-5 small molecules, PROTACs, and molecular glues. Additionally, Yilin contributes to the Cereblon E3 Ligase Modulator (CELMoD) platform and new target assessments across multiple disease areas. These contributions support Bristol Myers Squibb's mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.